Comanche Biopharma is a biotechnology company focused on the development of novel therapeutics for the treatment of serious and life-threatening diseases. The company leverages its proprietary technology platforms to discover and advance new treatments, with a particular emphasis on oncology and other critical therapeutic areas.

Mike Young

Thomas Scott Johnson

Comanche Biopharma

Comanche is a biopharmaceutical company developing novel siRNA molecules for the treatment of preeclampsia. Our purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining pregnancy and allowing for fetal maturation. We envision a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective and sustainable. Our mission is to prevent or treat preeclampsia at its root cause.

Atlas Venture

Lilly Asia Ventures

Longview Ventures

New Enterprise Associates

F-Prime Capital

Google Ventures

What a week we’ve had at Comanche Biopharma!

We announced an oversubscribed $75 million Series B financing by a top-tier syndicate of investors, endorsing our innovative science, our notable clinical progress with our lead drug candidate CBP-4888, and our experienced team of siRNA and maternal health experts tackling the extraordinary unmet needs in preeclampsia. 

We welcomed two new board members, Scott Gottlieb, M.D., Partner at New Enterprise Associates (NEA), and David Grayzel, M.D., Partner at Atlas Venture.

Most importantly, we helped to further amplify the impact of preeclampsia on mothers and their babies, in addition to families, healthcare systems and communities around the world. 

We must all do better for women and their families – and the Comanche team is driving toward a potential solution! 

ICYMI – read our press release: https://bit.ly/425OlVc

#preeclampsia #maternalhealth #pregnancy #siRNA #RNA

Thanks to Lisa Jarvis and Bloomberg Opinion for amplifying the significant unmet need surrounding preeclampsia, for sharing the important story of our Board member Allyson Felix's personal experience with preeclampsia, and for highlighting Comanche's advancement of a potential therapeutic solution for this serious condition, our lead siRNA drug candidate CPB-4888, with targets a root cause of the disease:  overproduction of the sFlt1 protein in the placenta. 

https://lnkd.in/ec_f9TVz

Thanks, Kyle LaHucik and Endpoints News for sharing the news today of our Series B financing and helping elevate awareness of the significant unmet needs in preeclampsia!

Our mission at Comanche:  to develop and make globally available the first treatment targeting a root cause of preeclampsia 

https://lnkd.in/ehZA_hjx

#preeclampsia #pregnancy #maternalhealth

We’re thrilled to announce the closing of an oversubscribed $75 million Series B financing. This capital investment by a top-tier syndicate will enable us to advance our mission to develop and make globally available the first treatment targeting a root cause of preeclampsia: over-production of the protein sFlt1 by the placenta.

Existing investors GV (Google Ventures), F-Prime Capital, Lilly Asia Ventures 礼来亚洲基金, and Longview Healthcare Ventures participated in the Series B round, joined by new investors New Enterprise Associates (NEA), who led the round, and Atlas Venture. 

Concurrent with the Series B raise, Scott Gottlieb, M.D., Partner at NEA and former Commissioner of the FDA, and David Grayzel, M.D., Partner at Atlas Venture, have joined our Board of Directors.

Read our press release to learn more about the extraordinary, complex unmet needs in preeclampsia, and our breakthrough science and drug candidate, CBP-4888, to potentially deliver a solution: https://bit.ly/425OlVc

#preeclampsia #maternalhealth #pregnancy #siRNA #RNA

Honored to be recognized as part of the Fierce 15 by Fierce Biotech at their 2023 Summit. Our commitment to addressing preeclampsia is unwavering. Thanks to our team and partners for their dedication to maternal health. #Fierce15 #FierceBiotechSummit #ComancheBiopharma

Comanche Biopharma applauds our Board member, Allyson Felix, on the launch of 'The Felix Runner' by Saysh. Her commitment to excellence is evident in every stride she takes, both on the track and in business.

Thank you Nasdaq for amplifying our #Fierce15 moment! #ComancheBiopharma #NASDAQ

We are honored to announce that Comanche Biopharma has been selected for Fierce Biotech’s 2023 #Fierce15, positioning us as one of the most promising biotechs in the industry. With a fierce dedication to addressing the escalating maternal health crisis, our team is working relentlessly to develop our novel siRNA investigational drug for the treatment of preterm #preeclampsia. We celebrate the dedication of our team and extend congratulations to fellow Fierce15 winners for their role in driving innovation forward.

Fierce Biotech’s 2023 Fierce15 special report: https://lnkd.in/dyTtvhxY

#Fierce15 #ComancheBiopharma #RNA #EndPreeclampsia #MaternalHealth

Comanche Biopharma Strengthens Board of Directors with Appointment of Dr. Ann Taylor

Comanche Biopharma is pleased to announce the appointment of Ann Taylor, M.D. to its Board of Directors. Dr. Taylor brings a wealth of experience and expertise, having held academic positions at Harvard Medical School and key leadership roles at Pfizer, Novartis, and AstraZeneca.

“We are honored to welcome Dr. Ann Taylor to our Board of Directors,” said Scott Johnson, M.D., CEO of Comanche Biopharma. “Her extensive background in academic medicine, the field of reproductive endocrinology, and clinical drug development will be instrumental as we enter the clinical stage of our company.”

Dr. Taylor's distinguished career includes serving as the former Chief Medical Officer at AstraZeneca, where she championed patient advocacy and led groundbreaking research and development initiatives. Her leadership at Novartis (NIBR) involved spearheading cross-functional teams focused on cardiovascular and metabolic diseases research. Additionally, at Pfizer, she was the Clinical Lead for the early obesity portfolio. 

Expressing her enthusiasm for the appointment, Dr. Taylor stated, "I am excited to contribute to Comanche's mission of addressing the global maternal health crisis as a member of the Board of Directors. Their commitment to improving outcomes in pregnancies complicated by preeclampsia aligns perfectly with my passion for patient-centered, high-quality healthcare."

Dr. Taylor's addition to the Board underscores Comanche Biopharma's ongoing commitment to augmenting its leadership with seasoned professionals who offer diverse perspectives and specialized expertise. With her deep understanding of clinical strategy and pharmaceutical leadership, Dr. Taylor will play a vital role in Comanche’s mission to advance maternal health globally.

Allyson Felix, the most decorated female Olympian in track and field history, is also a tireless advocate for maternal health. Her extraordinary journey on the track is paralleled by her personal journey off the track as a mother who faced a severe complication during her pregnancy - preeclampsia. This life-threatening condition brought her face-to-face with a serious health challenge and amplified her strength and resilience.  

Allyson's experience serves as a powerful reminder that preeclampsia does not discriminate and can impact anyone. At Comanche Biopharma we are truly honored to have Allyson Felix on our team.

Metric
Company Name	Comanche Biopharma
Symbol
MSH ID	COM:COMANCHEBIOPHARMA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	22
Website	comanchebiopharma.com
LinkedIn	comanche-biopharma
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:COMANCHEBIOPHARMA

Comanche Biopharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue